BRCA1 and neoplasm: On the other hand, PCa patients harboring BRCA1/2 mutations could possibly benefit to a greater degree from combination of apalutamide and EBRT compared to BRCA1/2 wild-type patients, as intrinsic HR repair defects in these patients plus compromised NHEJ repair by apalutamide would render the tumor cells exquisitely vulnerable to IR.